Abstract
Clinical studies on sulbactam/cefoperazone (SBT/CPZ) were carried out and the results were as follows: Eleven patients (pneumonia 8, acute purulent arthritis of the knee joint 1, urinary tract infection 2) were treated with SBT/CPZ, in doses of 30-67mg/kg divided 3 times per day for 3-6 1/3 days intravenously. The overall efficacy rate was 100%. As to adverse reaction, diarrhea was observed in 1 case. Abnormal laboratory data were noted in 2 cases (GPT elevation in 1, and eosinophilia and GPT elevation in 1).